JPS6253485B2 - - Google Patents
Info
- Publication number
- JPS6253485B2 JPS6253485B2 JP58116249A JP11624983A JPS6253485B2 JP S6253485 B2 JPS6253485 B2 JP S6253485B2 JP 58116249 A JP58116249 A JP 58116249A JP 11624983 A JP11624983 A JP 11624983A JP S6253485 B2 JPS6253485 B2 JP S6253485B2
- Authority
- JP
- Japan
- Prior art keywords
- micrograms
- composition
- pyridine
- weight
- cell wall
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 47
- 239000000284 extract Substances 0.000 claims description 37
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 23
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 23
- 210000004520 cell wall skeleton Anatomy 0.000 claims description 22
- 108010039939 Cell Wall Skeleton Proteins 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 241000186216 Corynebacterium Species 0.000 claims description 12
- 244000005700 microbiome Species 0.000 claims description 12
- 239000003921 oil Substances 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 210000002421 cell wall Anatomy 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 235000000346 sugar Nutrition 0.000 claims description 7
- 241001467552 Mycobacterium bovis BCG Species 0.000 claims description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 239000003599 detergent Substances 0.000 claims description 5
- 241000186363 Mycobacterium kansasii Species 0.000 claims description 4
- 241000187480 Mycobacterium smegmatis Species 0.000 claims description 4
- 241000187563 Rhodococcus ruber Species 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 241000187481 Mycobacterium phlei Species 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 2
- NSFMUHNGROVPRE-UHFFFAOYSA-N 7-hexyloctadecane Chemical compound CCCCCCCCCCCC(CCCCCC)CCCCCC NSFMUHNGROVPRE-UHFFFAOYSA-N 0.000 claims description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 2
- 229940059904 light mineral oil Drugs 0.000 claims description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 2
- 229940032094 squalane Drugs 0.000 claims description 2
- 229940031439 squalene Drugs 0.000 claims description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000037164 Collema parvum Species 0.000 description 2
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 2
- 241000186367 Mycobacterium avium Species 0.000 description 2
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000012134 supernatant fraction Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000187678 Nocardia asteroides Species 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000033772 system development Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39382282A | 1982-06-30 | 1982-06-30 | |
| US393822 | 1982-06-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS601133A JPS601133A (ja) | 1985-01-07 |
| JPS6253485B2 true JPS6253485B2 (en, 2012) | 1987-11-10 |
Family
ID=23556390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58116249A Granted JPS601133A (ja) | 1982-06-30 | 1983-06-29 | 微生物由来の精製されたピリジン可溶性抽出物を含有する医薬組成物 |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JPS601133A (en, 2012) |
| CA (1) | CA1206416A (en, 2012) |
| DE (1) | DE3323093C2 (en, 2012) |
| FR (1) | FR2536280B1 (en, 2012) |
| GB (1) | GB2122896B (en, 2012) |
| IT (1) | IT1163623B (en, 2012) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4663306A (en) * | 1983-09-23 | 1987-05-05 | Ribi Immunochem Research, Inc. | Pyridine-soluble extract-refined detoxified endotoxin composition and use |
| US4803070A (en) * | 1986-04-15 | 1989-02-07 | Ribi Immunochem Research Inc. | Immunological emulsion adjuvants for polysaccharide vaccines |
| BE1007823A3 (fr) * | 1993-12-10 | 1995-10-31 | Anda Biolog Sa | Utilisation d'une composition comprenant au moins un antigene et/ou un ou plusieurs fragments de cet antigene pour l'obtention d'un medicament destine au traitement et/ou a la prevention du cancer. |
| CN1230184C (zh) | 1998-07-16 | 2005-12-07 | 东市郎 | 以细菌的菌体成分为有效成分的癌免疫治疗用制剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2189021A1 (en) * | 1972-06-20 | 1974-01-25 | Anvar | Non-arthrogenic immunological adjuvants - obtained by extraction of lipid-free mycobacterial residues |
| US3976544A (en) * | 1973-06-19 | 1976-08-24 | The Agence Nationale De Valorisation De Le Recherche | Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction |
| JPS5428813A (en) * | 1977-08-09 | 1979-03-03 | Yuuichi Yamamura | Solid preparation containing cell membrane extract substance used as suspension when using same |
-
1983
- 1983-06-20 CA CA000430716A patent/CA1206416A/en not_active Expired
- 1983-06-27 DE DE3323093A patent/DE3323093C2/de not_active Expired
- 1983-06-29 JP JP58116249A patent/JPS601133A/ja active Granted
- 1983-06-29 FR FR8310788A patent/FR2536280B1/fr not_active Expired
- 1983-06-29 IT IT21853/83A patent/IT1163623B/it active
- 1983-06-30 GB GB08317742A patent/GB2122896B/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IT1163623B (it) | 1987-04-08 |
| GB2122896A (en) | 1984-01-25 |
| FR2536280B1 (fr) | 1987-02-20 |
| FR2536280A1 (fr) | 1984-05-25 |
| DE3323093C2 (de) | 1986-10-16 |
| GB8317742D0 (en) | 1983-08-03 |
| CA1206416A (en) | 1986-06-24 |
| IT8321853A1 (it) | 1984-12-29 |
| IT8321853A0 (it) | 1983-06-29 |
| JPS601133A (ja) | 1985-01-07 |
| DE3323093A1 (de) | 1984-01-05 |
| GB2122896B (en) | 1986-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3318567C2 (de) | Therapeutisches Mittel, enthaltend gereinigtes, entgiftetes Endotoxin, Zellwandgerüst und Trehalosedimycolat | |
| KR870000842B1 (ko) | 정제 해독된 내독소 및 그의 제조방법 | |
| DE3833319C2 (en, 2012) | ||
| US4520019A (en) | Stable composition and preparation thereof | |
| JPS6241214B2 (en, 2012) | ||
| US4505900A (en) | Refined detoxified endotoxin product | |
| JPS6234730B2 (en, 2012) | ||
| CH664897A5 (de) | Gereinigtes, entgiftetes endotoxin enthaltende pharmazeutische zusammensetzung. | |
| US4504473A (en) | Pyridine soluble extract of a microorganism | |
| US4505899A (en) | Refined detoxified endotoxin product | |
| US4239498A (en) | Method of preparing thymic factors and composition | |
| US4505903A (en) | Pyridine soluble extract of a microorganism | |
| JPS6253485B2 (en, 2012) | ||
| US4503048A (en) | Pyridine soluble extract of a microorganism | |
| DK153443B (da) | Fremgangsmaade til fremstilling af fast farmaceutisk praeparat indeholdende cellevaegsskelet fra nocardia rubra | |
| JPS6254774B2 (en, 2012) | ||
| CA1202903A (en) | Stable composition and preparation thereof | |
| Butler et al. | Combined immunostimulation in the prevention of tumor take in mice using endotoxins, their derivatives, and other immune adjuvants | |
| US4613504A (en) | Pyridine-soluble extracts of microorganisms | |
| CA1209504A (en) | Pyridine soluble extract of a microorganism | |
| KR820000420B1 (ko) | 세포의 벽조직을 구성하는 고형화된 제약 조성물의 제조방법 | |
| JPH0366316B2 (en, 2012) |